US-based protein analysis technology developer Encodia closed a $75m series C round today featuring GV and Nan Fung Life Sciences, respective subsidiaries of internet technology conglomerate Alphabet and property development group Nan Fung.
The round was co-led by Northpond Ventures and Deerfield Management and included Alexandria Venture Investments, a vehicle for life sciences real estate investment trust Alexandria Real Estate Equities, as well as Arch Venture Partners, Biomatics Capital, Decheng Capital and Tao Capital.
Encodia is commercialising large-scale protein analytics through a benchtop instrument. The company, which was spun out of Washington University in St Louis, will use the investment to accelerate platform development.
Sharon Kedar of Northpond and Andrew ElBardissi of Deerfield have been appointed to Encodia’s board of directors in connection with the series C round.
Encodia does not appear to have disclosed any previous funding but identified Nan Fung Life Sciences, Arch Venture Partners, Biomatics Capital, Decheng Capital and Tao Capital as returning backers.
The original version of this article appeared on our sister site, Global University Venturing.